Market Overview

Translate Bio Announces Pricing of Initial Public Offering

Share:

Translate Bio, Inc. (NASDAQ:TBIO) a clinical-stage messenger RNA (mRNA)
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or gene
dysfunction, today announced the pricing of its initial public offering
of 9,350,000 shares of its common stock at a price to the public of
$13.00 per share, for total gross proceeds of approximately $121.6
million, before deducting underwriting discounts and commissions and
expenses payable by Translate Bio. In addition, Translate Bio has
granted the underwriters a 30-day option to purchase up to 1,402,500
additional shares of common stock at the public offering price, less
underwriting discounts and commissions, to cover over-allotments, if
any. All of the shares are being offered by Translate Bio. The shares
are expected to begin trading on the Nasdaq Global Select Market on June
28, 2018 under the symbol "TBIO." The offering is expected to close on
July 2, 2018, subject to customary closing conditions.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180627006359/en/

Citigroup, Leerink Partners and Evercore ISI are acting as joint
book-running managers for the offering.

A registration statement relating to the shares being sold in this
offering was declared effective by the Securities and Exchange
Commission on June 27, 2018. The offering is being made only by means of
a prospectus. When available, a copy of the final prospectus may be
obtained by contacting Citigroup Global Markets Inc. c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by
telephone at 1-800-831-9146; Leerink Partners LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at 1-800-808-7525, ext. 6132, or by email at syndicate@leerink.com;
or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, New York 10055, by telephone at
888-474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there be any
sale of, these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Translate Bio
Translate Bio is a clinical-stage mRNA
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or gene
dysfunction.

Forward-Looking Statements
Statements in this press release
about future expectations, plans and prospects, as well as any other
statements regarding matters that are not historical facts, may
constitute "forward-looking statements" within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements relating to the expected
trading commencement and closing dates. The words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend," "may,"
"plan," "potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties related to market
conditions and the completion of the public offering on the anticipated
terms or at all, and other factors discussed in the "Risk Factors"
section of the preliminary prospectus filed with the Securities and
Exchange Commission. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Translate Bio
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com